Author Affiliations: Department of Cardiology, Charité Campus Virchow-Klinikum, Berlin, Germany (email@example.com).
In Reply: We agree with Dr Slatopolsky that many aspects merit attention in the discussion of paricalcitol. We also agree that paricalcitol is effective and even faster than 1,25-hydroxyvitamin D3 in the suppression of elevated levels of parathyroid hormone.1 This is also the case in patients with significantly elevated levels of phosphorus, a subgroup of patients usually deemed resistant to 1,25-hydroxyvitamin D3.2 However, in the space of an editorial, we were not able to provide a complete overview of paricalcitol and therefore primarily focused on summarizing the evidence in the field of CKD and left ventricular hypertrophy, which was the area of concern for the PRIMO trial. No beneficial effects of paricalcitol have yet been demonstrated in this regard.
Anker SD, von Haehling S. Vitamin D Therapy and Cardiac Function in Chronic Kidney Disease—Reply. JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4178